aminocaproic acid has been researched along with Hematologic Malignancies in 4 studies
Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.
6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aminocaproic acid is frequently used in patients with hematologic malignancy that present with thrombocytopenia with or without hemorrhage." | 7.88 | Thromboembolic complications following aminocaproic acid use in patients with hematologic malignancies. ( Elefritz, JL; Juhl, RC; Li, J; Roddy, JVF; Wang, TF, 2018) |
| "Aminocaproic acid is frequently used in patients with hematologic malignancy that present with thrombocytopenia with or without hemorrhage." | 3.88 | Thromboembolic complications following aminocaproic acid use in patients with hematologic malignancies. ( Elefritz, JL; Juhl, RC; Li, J; Roddy, JVF; Wang, TF, 2018) |
| "The antifibrinolytic aminocaproic acid is widely used in surgical settings to prevent blood loss and decrease transfusion requirements, and small observational studies have suggested that aminocaproic acid may be useful in the setting of malignancy-related bleeding." | 3.83 | Aminocaproic acid use in hospitalized patients with hematological malignancy: a case series. ( Drucker, A; Dzik, W; Li, A; Marshall, A, 2016) |
| " Patients with lymphoma received carmustine 300 mg/m(2), cyclophosphamide 1,500 mg/m(2) on days 2 through 5 (total 6 g/m(2)), and etoposide 700 mg/m(2) per day on days 2 through 4 (total 2,100 mg/m(2))." | 3.81 | Autologous Stem-Cell Transplantation Without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah's Witnesses. ( Ford, PA; Grant, SJ; Keck, G; Mick, R, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Juhl, RC | 1 |
| Roddy, JVF | 1 |
| Wang, TF | 1 |
| Li, J | 1 |
| Elefritz, JL | 1 |
| Antun, AG | 1 |
| Gleason, S | 1 |
| Arellano, M | 1 |
| Langston, AA | 1 |
| McLemore, ML | 1 |
| Gaddh, M | 1 |
| el Rassi, F | 1 |
| Bernal-Mizrachi, L | 1 |
| Galipeau, J | 1 |
| Heffner, LT | 1 |
| Winton, EF | 1 |
| Khoury, HJ | 1 |
| Marshall, A | 1 |
| Li, A | 1 |
| Drucker, A | 1 |
| Dzik, W | 1 |
| Ford, PA | 1 |
| Grant, SJ | 1 |
| Mick, R | 1 |
| Keck, G | 1 |
4 other studies available for aminocaproic acid and Hematologic Malignancies
| Article | Year |
|---|---|
Thromboembolic complications following aminocaproic acid use in patients with hematologic malignancies.
Topics: Adult; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Catheterization, Central Venous; Catheters, | 2018 |
Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Aminocaproic Acid; Antifibrinolyti | 2013 |
Aminocaproic acid use in hospitalized patients with hematological malignancy: a case series.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Aminocaproic Acid; Female; Hematologic | 2016 |
Autologous Stem-Cell Transplantation Without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah's Witnesses.
Topics: Adult; Aged; Aminocaproic Acid; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; C | 2015 |